Tempus
Tempus, Genialis Partner to Develop RNA-Based Cancer Biomarker Algorithms
Genialis will use Tempus' multimodal dataset to develop new RNA-based algorithms for a variety of cancers.
Personalis, Tempus Expand MRD Diagnostics Partnership to Include Biopharma
Tempus will now offer Personalis' NeXT Personal Dx minimal residual disease assay to pharmaceutical and biotech customers.
Lung Cancer Study Suggests Concurrent RNA, DNA Testing Picks up Actionable SVs
RNA sequencing unearthed actionable structural variants missed with DNA-only sequencing based on tumor assays on 5,570 advanced non-small cell lung cancer cases.
Tempus Strikes Cancer Drug Research Deal With JW Pharmaceutical
As part of the collaboration, the companies will use Tempus' biological modeling platform and collection of patient-derived cancer organoid models.
Avacta Therapeutics, Tempus Partner to Advance FAP-Based Peptide Drug Conjugates
Avacta will tap into Tempus' real-world data and machine-learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.